XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
XORTX Therapeutics announced an anticipated Clinical Trial Application planned for filing with Health Canada for XRx-026 (XORLO™), describing a two-part study XRX-OXY-102 that will evaluate their proprietary oxypurinol formulation in gout. The company says conducting part one in Canada is intended to support its planned NDA filing with the U.S. Food and Drug Administration.